The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
It could be Activ-2 that delivers the blockbuster Doc...just sayin :-)
Yes its great news and hope there is a serious push for the hospital lab test. Pretty cool you could give patients a test that predicst with 75% accuracy who will likely go on to develop severe disease after first being admitted to hospital.
This would enable Drs to change treatment courses / protocol etc to bring about better outcomes. More precision in choosing what anti inflammatory drugs would function best in a given situation or which people get interferon etc.
You also could likely manage beds / ICU better.
Joey - Wow that is an amazing paper. So rare to find such compelling datasets. Synairgen surely in the thick of it with these findings. Let's hope we are approaching the tipping point for public health to start recognising the interferon anti viral story, not just the symptomatic anit inflammatory one.
Great post JoeyD. That has got to be the key to changing the course of this pandemic.
Hi Ghia and anyone else interested
Here is the full lancet paper - https://www.sciencedirect.com/science/article/pii/S2352396421001328
Fantastic work by these scientists creating a genetic biomarker model to predict disease severity. Will be known as the EPICOVID signature. Essentially they ran tests on people and performed a genetic test They found 20 genes were linked to severe outcomes of Covid, 7 of which were linked to interferon.
Significantly overrepresented genes (hypergeometric test, P value = 2.14e-06) associated with GO biological processes included those of “immune response”, “type I interferon signalling pathway”, “interferon-gamma-mediated signalling pathway”, “antigen processing and presentation”, “defence response to virus”, “cytokine-mediated signalling pathway” and “inflammatory response”. These processes are highly relevant to the degree of potential response to COVID-19 infection, since they are related to the capacity of the immune system to respond to viral infections. In this regard, the 20 genes containing the CpG methylation variants associated with COVID-19 severity include an overrepresentation of genes that mediate the response to interferon, a key pathway in the physiopathological pathway of the disease
* 13% of people in the population match the EPICOVID signature and in theory means they will likely develop severe Covid.
* In hospital they found between 83.5 and 90% of patients with severe Covid matched the EPICOVID signature.
Using this approach, we obtained an epigenomic signature, hereafter referred to as the EPICOVID signature, that predicted COVID-19 severity with 90.18% accuracy (mean Kappa = 0.804). Supervised hierarchical clustering using the COVID-19 signature also clearly distinguished two branches that were significantly enriched with respect to each condition: those who were asymptomatic/paucisymptomatic and those with respiratory failure. We observed that the EPICOVID-positive signature was also associated with worse COVID-19 clinical course with a specificity of 88.18%, a sensitivity of 77.78%, and positive and negative predictive values (PPV and NPV) of 84.34% and 82.91%, respectively. The accuracy was 83.5% and the mean Kappa 0.6643.
* Regards to using this testing in a hospital setting as a predictor of disease outcomes then the answer in theory is yes.
The use of more user-friendly PCR approaches, such as the described pyrosequencing technology, could facilitate the analyses at the common hospital laboratory level. In this regard, it is worth noting that, if instead of the comprehensive EPICOVID signature we selected the top five CpG sites associated with severity according to P-value (Table S2), its single differential methylation status was still ossociated with COVID-19 severity (69%-76% accuracy range). Thus, a more restricted signature derived from the heatmap and clustering analyses might be useful in future prospective multicentre studies.
Seems we need Extra Ifn for breakfast it wards off all manner of medical issues.
Surely someone with the power to do something is taking note ?
Go away dumb, and play on the buses
50% of the time SNG is effective every time ;)
Excellent find - more exciting news
146% pf the world population is the minimum I would accept. Lol.
This sh i te again?
Great find, feels like we're picking up traction. The science has always held up, and I have no doubt we'll keep seeing future papers supporting it.
best ask dumbpunter, he's our percentages expert.
How excited are you ghia on a scale of 1=10?
:)
Nice paper posted on ADVFN that explains in a nutshell the market SNG could serve.
Potentially 10-25% of the global population.
"We decided to study more than 400 people who had tested positive for COVID-19 who did not belong to any of these risk groups and study their genetic material depending on whether they had not had symptoms, or they were very mild, or instead they had been admitted to the hospital requiring respiratory assistance. We found that there were epigenetic variations, the chemical switches that regulate DNA activity, in the individuals positive for the virus who developed a severe COVID-19. These modifications occurred mainly in genes associated with an excessive inflammatory response and in genes that reflect an overall worse state of health. Interestingly, 13% of the world population presents this epigenetic signature (EPICOVID), thus, this is the group at maximum risk that we must take special care of. " - concludes the researcher.
"These results complement and confirm the implication of the interferon-directed antiviral response and its importance in the evolution of the disease, as we explained in a complete genome sequencing study published in the journal Science last September," says Dr. Pujol and continues: "With these advanced tools of personalized medicine, both in the field of genomics and epigenomics, it is possible to design predictive models that allow detecting patients at risk of a worse prognosis and therefore improve their treatment and avoid the collapse of the health system."
htTps://www.eurekalert.org/pub_releases/2021-04/jclr-doe041521.php